Prophylactic Bevacizumab May Mitigate Radiation Injury: An Experimental Study


Aslan A., KAYA Z. B. , Bulduk E. B. , Ocal O., Ucar M., Erpolat O. P. , ...Daha Fazla

WORLD NEUROSURGERY, cilt.116, 2018 (SCI İndekslerine Giren Dergi) identifier identifier identifier

Özet

BACKGROUND: Stereotactic radiosurgery (SRS) is widely used to treat brain pathologies alone or in concert with other treatment modalities. However, there are some side effects, such as radiation injury characterized by edema and necrosis in peripheral tissues, that must be managed. A new treatment agent against this side effect is bevacizumab, which targets increased vascular endothelial growth factor (VEGF) as a prominent etiologic factor in radiation injury. In this study, we created a rat experimental model to describe the effects of both radiation and the anti-VEGF monoclonal antibody bevacizumab following high-dose SRS, and to compare the effects of prophylactic and delayed-onset bevacizumab treatment.